Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Stock Chart & Stats
$115.37
$1.50(0.96%)
At close: 4:00 PM EST
$115.37
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $130.23
Previous CloseN/A
Volume137.72K
Average Volume (3M)819.03K
Market Cap
$6.84B
Enterprise Value$6.76B
Total Cash (Recent Filing)$278.76M
Total Debt (Recent Filing)$139.64M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding58,078,810
10 Day Avg. Volume936,555
30 Day Avg. Volume819,034
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue13.33
Enterprise Value/Gross Profit16.73
Enterprise Value/Ebitda-46.25
Forecast
1Y Price Target
$133.45Price Target Upside15.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$613.85M
Bulls Say, Bears Say
Bulls Say
Commercial RolloutFaster-than-expected device placements and encouraging insurer discussions for the new corneal system suggest the product rollout could gain rapid commercial traction and expand patient access.
Financial Strength And MarginsHigh gross margins combined with a sizable cash and investment position provide capacity to fund commercialization and pipeline programs without immediate dilution, supporting growth execution.
Label Expansion And Re-administrationRegulatory approval permitting repeat iDose procedures broadens treatment options and is likely to increase the pool of eligible patients and repeat sales as clinicians adopt re-administration.
Bears Say
Commercialization Cost PressureElevated operating expenses tied to the corneal system launch will increase commercialization costs and could weigh on near-term profitability as investment ramps up.
Coverage And Regulatory RiskA potential Medicare local coverage decision or stricter label requirements could restrict iDose eligibility and reduce procedural uptake if coverage is constrained.
Transition And Stockpiling HeadwindPlanned patient stockpiling and the transition from the legacy corneal therapy to the new system could depress corneal health revenue and create near-term sales volatility before volumes recover.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $130.23 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $6.84B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is May 06, 2026 which is in 62 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Feb 17, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.084.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.27.
How many shares outstanding does Glaukos have?
Glaukos has 58,078,810 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went up 13.466%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$133.45 (15.67% Upside)
$133.45 (15.67% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 702.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.87%
12-Months-Change
Fundamentals
Return on Equity
-26.38%
Trailing 12-Months
Asset Growth
-10.21%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported multiple substantial positive developments: record Q4 and FY2025 revenue, strong iDose TR adoption and revenue (~$136M in 2025), FDA approval and active commercial launch progress for Epioxa, tangible early payer engagement and site deployments, and continued pipeline momentum across several programs. Challenges and near-term headwinds were acknowledged — including Q4 iDose sequential dynamics, expected transition volatility from Photrexa to Epioxa (temporary misc J-code impacts and prior-authorization delays), international competitive trialing, and higher OpEx to support launches. Overall, the positives (record results, robust product momentum, successful approval and launch activities, and clear guidance) materially outweigh the manageable and largely execution/timing-related lowlights.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$133.45
▲(15.67% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.99% Insiders
33.37% Mutual Funds
17.83% Other Institutional Investors
21.36% Public Companies and
Individual Investors